Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Sponsor: Fudan University
Summary
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
Official title: A Study of Compared Adjuvant Serplulimab and Trastuzuma and Chemotherapy vs Chemotherapy Only in Her-2 Positive Gastric Cancer With II-III Stage Following Curative Resection
Key Details
Gender
All
Age Range
20 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
114
Start Date
2023-01-01
Completion Date
2029-01-01
Last Updated
2024-03-12
Healthy Volunteers
No
Conditions
Interventions
Serplulimab
Serplulimab: 4.5mg/Kg on day 1
Trastuzuma
Trastuzuma: 8mg/Kg ( the first cycle),6mg/Kg (the rest of cycles) on day 1
Chemotherapy
Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China